StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

Arvinas ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Arvinas's ebitda for the twelve months ending Jun 30, 2026 was -$15.20M. For fiscal 2025 it was -$115.50M. The highest annual figure on record is -$24.41M in fiscal 2017.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$115.50M–
FY2024Dec 31, 2024-$245.60M–
FY2023Dec 31, 2023-$396.70M–
FY2022Dec 31, 2022-$256.90M–
FY2021Dec 31, 2021-$183.60M–
FY2020Dec 31, 2020-$117.60M–
FY2019Dec 31, 2019-$49.90M–
FY2018Dec 31, 2018-$43.10M–
FY2017Dec 31, 2017-$24.41M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$164.80M–
Q1 FY2026Mar 31, 2026-$63.10M-187.5%
Q4 FY2025Dec 31, 2025-$73.90M–
Q3 FY2025Sep 30, 2025-$43.00M–
Q2 FY2025Jun 30, 2025-$70.70M–
Q1 FY2025Mar 31, 2025$72.10M–
Q4 FY2024Dec 31, 2024-$57.10M–
Q3 FY2024Sep 30, 2024-$59.20M–
Q2 FY2024Jun 30, 2024-$47.30M–
Q1 FY2024Mar 31, 2024-$82.10M–
Q4 FY2023Dec 31, 2023-$164.10M–
Q3 FY2023Sep 30, 2023-$72.70M–
Q2 FY2023Jun 30, 2023-$73.40M–
Q1 FY2023Mar 31, 2023-$86.50M–
Q4 FY2022Dec 31, 2022-$73.90M–
Q3 FY2022Sep 30, 2022-$62.70M–
Q2 FY2022Jun 30, 2022-$64.30M–
Q1 FY2022Mar 31, 2022-$56.20M–
Q4 FY2021Dec 31, 2021-$46.20M–
Q3 FY2021Sep 30, 2021-$46.10M–
Q2 FY2021Jun 30, 2021-$50.70M–
Q1 FY2021Mar 31, 2021-$40.60M–
Q4 FY2020Dec 31, 2020-$38.07M–
Q3 FY2020Sep 30, 2020-$30.89M-617.1%
Q2 FY2020Jun 30, 2020-$25.85M–
Q1 FY2020Mar 31, 2020-$22.79M–
Q4 FY2019Dec 31, 2019-$22.21M–
Q3 FY2019Sep 30, 2019$5.97M–
Q2 FY2019Jun 30, 2019-$18.11M–
Q1 FY2019Mar 31, 2019-$15.57M–
Q4 FY2018Dec 31, 2018-$16.72M–
Q3 FY2018Sep 30, 2018-$13.87M–
Q2 FY2018Jun 30, 2018-$8.35M–
Q1 FY2018Mar 31, 2018-$4.16M–
Q4 FY2017Dec 31, 2017-$5.21M–

More Arvinas figures

See a number that looks wrong?